The Food and Drug Administration (FDA) has announced a joint public meeting of the agency's Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee to be held February 2005.
The committees will discuss the overall benefit-to-risk considerations (including cardiovascular and gastrointestinal concerns) for COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) and related medicines.
Members of the public are encouraged to participate in this meeting.
| Oral presentations from the public will be scheduled on February 17|
Interested persons may present data, information or views, orally or in writing, on issues pending before the committees.
Oral presentations from the public will be scheduled between 1:00 p.m. and 3:00 p.m. on February 17.
Time allotted for each presentation may be limited.
Those desiring to make formal oral presentations should register to speak at the meeting before February 4, 2005.